� How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
� The market forecasts indicate that Japan will contribute the most to the Asia- Pacific market value due to the emergence of novel therapies.
� How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
� How could changes in risk factors such as population age, smoking habits and pollution influence the market?
� Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $ 10m to over $ 1 billion.
� How do deal frequency and value compare between target families and molecule types?
� What were the terms and conditions of key licensing deals?
Reasons to buy This report will allow you to-
� Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
� Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
� Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
� Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
� Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.